Compare Citius Pharmaceuticals Inc (CTXR) vs Alphabet Inc Class A (GOOGL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Alphabet Inc Class A — how do they compare? Citius Pharmaceuticals Inc trades at $0.77 (market cap $20.01M), while Alphabet Inc Class A trades at $343.6 (market cap $4.20T). The key difference: Alphabet Inc Class A is far larger — about 209895.1× Citius Pharmaceuticals Inc's market cap, and Alphabet Inc Class A pays a 0.26% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | GOOGL | |
|---|---|---|
Market Cap | $20.01M | $4.20T |
Sector | Health | Media |
52-Week High | $1.82 | $402.62 |
52-Week Low | $0.48 | $199.32 |
Enterprise Value | $16.23M | $4.09T |
Dividend Yield | — | 0.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.7554, up 11.58% today, with a bullish technical signal from moving averages. The company reported a net loss of $37.43M for 2025, with a negative net income margin of -823.34%, but shows revenue growth from its LYMPHIR launch. Recent news highlights commercial expansion and positive clinical data presentations at ASCO 2026.
The outlook is speculative; analyst consensus is strongly bullish (83.3% Buy), but high cash burn and consistent earnings misses pose significant risks. Investment potential hinges on successful commercialization of LYMPHIR to achieve profitability.
Alphabet (GOOGL) trades at $344.00, down 3.78% on the day, with technical indicators showing bearish momentum below key resistance at $347. Fundamentally, the company demonstrates strong profitability with 54.77% net income margin and consistent earnings beats, though valuation multiples remain elevated with P/E at 17.25. Recent developments include YouTube subscription price increases and continued AI infrastructure investments.
The stock presents a compelling long-term opportunity given strong analyst consensus (85% buy ratings) and $426.28 price target, representing 24% upside. Key risks include antitrust scrutiny and tech sector rotation pressures, but Alphabet's AI leadership and diversified revenue streams support growth prospects despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Alphabet Inc Class A
Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →
